From: Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012
Age group | MUMPS in malesa number of cases | ORCHITIS - number (% of age group) of cases in males | ORCHITIS - number (%) of cases by number of doses | Odds ratiob (95 % CI) | Vaccine effectivenessb % (95 % CI) | ||||
---|---|---|---|---|---|---|---|---|---|
0 doses | 1 dose | 2 doses | 1 dose | 2 doses | 1 dose | 2 doses | |||
0 | 9 | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
1–4 | 140 | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
5–9 | 670 | 4 (0.6 %) | 0 (0.0 %) | 0 (0.0 %) | 4 (100.0 %) | ||||
10–14 | 1161 | 30 (2.6 %) | 2 (6.7 %) | 0 (0.0 %) | 28 (93.3 %) | 0.19 (0.04, 0.87) | 81 (13, 96) | ||
15–19 | 2088 | 219 (10.5 %) | 10 (4.6 %) | 1 (0.5 %) | 208 (95.0 %) | 0.38 (0.04, 3.61) | 0.26 (0.12, 0.55) | 62 (-261, 96) | 74 (45, 88) |
20–24 | 690 | 129 (18.7 %) | 50 (38.8 %) | 1 (0.8 %) | 78 (60.5 %) | 0.49 (0.06, 4.28) | 0.44 (0.29, 0.66) | 51 (-328, 94) | 56 (34, 71) |
25–34 | 608 | 232 (38.2 %) | 216 (93.1 %) | 1 (0.4 %) | 15 (6.5 %) | 0.49 (0.05, 4.75) | 0.40 (0.22, 0.73) | 51 (-375, 95) | 60 (27, 78) |
35–44 | 117 | 31 (26.5 %) | 31 (100.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
45–54 | 68 | 11 (16.2 %) | 11 (100.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
55–64 | 30 | 1 (3.3 %) | 1 (100.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
65+ | 6 | 1 (16.7 %) | 1 (100.0 %) | 0 (0.0 %) | 0 (0.0 %) | ||||
Total | 5587 | 658 (11.8 %) | 322 (48.9 %) | 3 (0.5 %) | 333 (50.6 %) | 0.21 (0.06, 0.70) | 0.17 (0.14, 0.20) | 79 (30, 94) | 83 (80, 86) |